bullish

Therapeuticsmd, Inc. (TXMD) - Thursday, May 23, 2024

0 View23 May 2024 12:00
Syndicated
SUMMARY
  • TherapeuticsMD has shifted to a healthcare royalty model through a licensing agreement with Mayne Pharmaceuticals
  • Downside risk is minimized by a minimum payment obligation in the agreement, with potential for significant upside
  • Despite near-term uncertainties, the company has access to additional funding and presents a compelling investment opportunity at its current stock price.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Value Investors Club
External reports (aggregated public sources)
Value Investors Club
Equity Bottom-UpEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Therapeuticsmd, Inc. (TXMD) - Thursday, May 23, 2024
    23 May 2024
x